

Jo-Anne H Young

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9183694/publications.pdf>

Version: 2024-02-01

151
papers

21,372
citations

28190

55
h-index

12910

131
g-index

156
all docs

156
docs citations

156
times ranked

15337
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 52, e56-e93.	2.9	2,434
2	Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2008, 46, 327-360.	2.9	2,432
3	Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, e1-e60.	2.9	1,861
4	Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global Perspective. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 1143-1238.	2.0	1,505
5	Micafungin versus Fluconazole for Prophylaxis against Invasive Fungal Infections during Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2004, 39, 1407-1416.	2.9	1,248
6	Treatment of Invasive Aspergillosis with Posaconazole in Patients Who Are Refractory to or Intolerant of Conventional Therapy: An Externally Controlled Trial. <i>Clinical Infectious Diseases</i> , 2007, 44, 2-12.	2.9	724
7	Epidemiology of <i>Aspergillus</i> Infections in a Large Cohort of Patients Undergoing Bone Marrow Transplantation. <i>Journal of Infectious Diseases</i> , 1997, 175, 1459-1466.	1.9	717
8	Executive Summary: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer: 2010 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2011, 52, 427-431.	2.9	635
9	Posaconazole Is Effective as Salvage Therapy in Zygomycosis: A Retrospective Summary of 91 Cases. <i>Clinical Infectious Diseases</i> , 2006, 42, e61-e65.	2.9	553
10	Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 828-837.	4.6	528
11	Posaconazole as Salvage Therapy for Zygomycosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 126-133.	1.4	523
12	Detection and identification of fungal pathogens in blood by using molecular probes. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1353-1360.	1.8	520
13	Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. <i>Bone Marrow Transplantation</i> , 2009, 44, 453-455.	1.3	320
14	Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. <i>Lancet Infectious Diseases</i> , The, 2011, 11, 284-292.	4.6	315
15	A Double-blind, Randomized, Controlled Trial of Amphotericin B Colloidal Dispersion versus Amphotericin B for Treatment of Invasive Aspergillosis in Immunocompromised Patients. <i>Clinical Infectious Diseases</i> , 2002, 35, 359-366.	2.9	308
16	Executive Summary: Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2016, 63, 433-442.	2.9	295
17	Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. <i>Journal of Infection</i> , 2006, 53, 337-349.	1.7	290
18	Randomized, Double-blind Clinical Trial of Amphotericin B Colloidal Dispersion vs. Amphotericin B in the Empirical Treatment of Fever and Neutropenia. <i>Clinical Infectious Diseases</i> , 1998, 27, 296-302.	2.9	287

#	ARTICLE	IF	CITATIONS
19	Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. <i>Blood</i> , 2006, 108, 2874-2880.	0.6	257
20	Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. <i>Blood</i> , 2008, 111, 5403-5410.	0.6	226
21	Genetic Diversity of Human Pathogenic Members of the <i>Fusarium oxysporum</i> Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin. <i>Journal of Clinical Microbiology</i> , 2004, 42, 5109-5120.	1.8	201
22	A Multicenter, Double-blind Trial of a High-dose Caspofungin Treatment Regimen versus a Standard Caspofungin Treatment Regimen for Adult Patients with Invasive Candidiasis. <i>Clinical Infectious Diseases</i> , 2009, 48, 1676-1684.	2.9	196
23	The Effect of Prophylactic Fluconazole on the Clinical Spectrum of Fungal Diseases in Bone Marrow Transplant Recipients with Special Attention to Hepatic Candidiasis: An Autopsy Study of 355 Patients. <i>Medicine (United States)</i> , 1998, 77, 246-254.	0.4	188
24	Efficacy of transfusion with granulocytes from G-CSF/dexamethasone-treated donors in neutropenic patients with infection. <i>Blood</i> , 2015, 126, 2153-2161.	0.6	184
25	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. <i>Lancet Infectious Diseases</i> , The, 2021, 21, e246-e257.	4.6	167
26	Histoplasmosis After Solid Organ Transplant. <i>Clinical Infectious Diseases</i> , 2013, 57, 1542-1549.	2.9	164
27	Comparison of six extraction techniques for isolation of DNA from filamentous fungi. <i>Medical Mycology</i> , 1998, 36, 299-303.	0.3	157
28	Higher Risk of Cytomegalovirus and <i>Aspergillus</i> Infections in Recipients of T Cell-Depleted Unrelated Bone Marrow: Analysis of Infectious Complications in Patients Treated with T Cell Depletion Versus Immunosuppressive Therapy to Prevent Graft-versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1487-1498.	2.0	148
29	A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. <i>Blood</i> , 2014, 124, 2921-2929.	0.6	145
30	Development of Fluconazole Resistance in <i>Candida albicans</i> Causing Disseminated Infection in a Patient Undergoing Marrow Transplantation. <i>Clinical Infectious Diseases</i> , 1997, 25, 908-910.	2.9	143
31	Aspects of Fungal Pathogenesis in Humans. <i>Annual Review of Microbiology</i> , 2001, 55, 743-772.	2.9	139
32	Nocardiosis After Bone Marrow Transplantation: A Retrospective Study. <i>Clinical Infectious Diseases</i> , 1997, 24, 1154-1160.	2.9	127
33	Infections after Transplantation of Bone Marrow or Peripheral Blood Stem Cells from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 359-370.	2.0	127
34	A Scheme for Defining Cause of Death and Its Application in the T Cell Depletion Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1469-1476.	2.0	126
35	Granulocyte Colony-stimulating Factor Administered In Vivo Augments Neutrophil-mediated Activity against Opportunistic Fungal Pathogens. <i>Journal of Infectious Diseases</i> , 1997, 175, 1012-1015.	1.9	124
36	Enterococcal Bacteremia Is Associated With Increased Risk of Mortality in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation. <i>Clinical Infectious Diseases</i> , 2012, 55, 764-770.	2.9	124

#	ARTICLE	IF	CITATIONS
37	Serious Infections after Unrelated Donor Transplantation in 136 Children: Impact of Stem Cell Source. <i>Biology of Blood and Marrow Transplantation</i> , 2005, 11, 362-370.	2.0	118
38	Micafungin alone or in combination with other systemic antifungal therapies in hematopoietic stem cell transplant recipients with invasive aspergillosis. <i>Transplant Infectious Disease</i> , 2009, 11, 89-93.	0.7	116
39	Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 1106-1115.	2.0	108
40	Phase I Study of Amphotericin B Colloidal Dispersion for the Treatment of Invasive Fungal Infections after Marrow Transplant. <i>Journal of Infectious Diseases</i> , 1996, 173, 1208-1215.	1.9	106
41	Hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: risk factors, graft source and survival. <i>Bone Marrow Transplantation</i> , 2015, 50, 1432-1437.	1.3	92
42	A Phase I-II Clinical Trial to Evaluate Removal of CD4 Cells and Partial Depletion of CD8 Cells From Donor Marrow for HLA-Mismatched Unrelated Recipients. <i>Blood</i> , 1999, 94, 2192-2199.	0.6	91
43	Comparison of Interferon- γ , Granulocyte Colony-Stimulating Factor, and Granulocyte-Macrophage Colony-Stimulating Factor for Priming Leukocyte-Mediated Hyphal Damage of Opportunistic Fungal Pathogens. <i>Journal of Infectious Diseases</i> , 1999, 179, 1038-1041.	1.9	91
44	Alternative donor hematopoietic cell transplantation for Fanconi anemia. <i>Blood</i> , 2015, 125, 3798-3804.	0.6	90
45	Human Herpesvirus 6 Infection after Hematopoietic Cell Transplantation: Is Routine Surveillance Necessary?. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1562-1568.	2.0	87
46	Impact of Cytomegalovirus (CMV) Reactivation after Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 215-222.	2.0	84
47	Infection prevention and control in health-care facilities in which hematopoietic cell transplant recipients are treated. <i>Bone Marrow Transplantation</i> , 2009, 44, 495-507.	1.3	77
48	Aspergillus Infections. <i>New England Journal of Medicine</i> , 2021, 385, 1496-1509.	13.9	74
49	HspE7 Treatment of Pediatric Recurrent Respiratory Papillomatosis: Final Results of an Open-Label Trial. <i>Annals of Otolaryngology, Rhinology and Laryngology</i> , 2005, 114, 730-737.	0.6	72
50	Monitoring and Preemptive Rituximab Therapy for Epstein-Barr Virus Reactivation after Antithymocyte Globulin Containing Nonmyeloablative Conditioning for Umbilical Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 287-291.	2.0	72
51	Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1636-1645.	2.0	71
52	Human Parainfluenza Virus Infection after Hematopoietic Stem Cell Transplantation: Risk Factors, Management, Mortality, and Changes Over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2012, 18, 1580-1588.	2.0	68
53	An International Comparison of Current Strategies to Prevent Herpesvirus and Fungal Infections in Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 664-673.	2.0	65
54	Cytomegalovirus enteritis among hematopoietic stem cell transplant recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2001, 7, 674-679.	2.0	58

#	ARTICLE	IF	CITATIONS
55	Allogeneic Hematopoietic Cell Transplantation in Human Immunodeficiency Virus-Positive Patients with Hematologic Disorders: A Report from the Center for International Blood and Marrow Transplant Research. <i>Biology of Blood and Marrow Transplantation</i> , 2009, 15, 864-871.	2.0	58
56	Current practices for treatment of respiratory syncytial virus and other non-influenza respiratory viruses in high-risk patient populations: a survey of institutions in the Midwestern Respiratory Virus Collaborative. <i>Transplant Infectious Disease</i> , 2016, 18, 210-215.	0.7	58
57	Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients. <i>Haematologica</i> , 2007, 92, 1029-1036.	1.7	57
58	A Randomized Trial of One versus Two Doses of Influenza Vaccine after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 109-116.	2.0	57
59	Bacteremia in Blood or Marrow Transplantation Patients: Clinical Risk Factors for Infection and Emerging Antibiotic Resistance. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 102-108.	2.0	50
60	Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2019, 54, 1254-1265.	1.3	47
61	INFECTIONS IN RECIPIENTS OF BLOOD AND MARROW TRANSPLANTATION. <i>Hematology/Oncology Clinics of North America</i> , 1999, 13, 1065-1089.	0.9	46
62	Finding the Dose for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 766-769.	2.3	46
63	Safe living after hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2009, 44, 509-519.	1.3	44
64	Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 440-443.	2.0	41
65	Bloodstream Infection Due to Vancomycin-resistant Enterococcus Is Associated With Increased Mortality After Hematopoietic Cell Transplantation for Acute Leukemia and Myelodysplastic Syndrome: A Multicenter, Retrospective Cohort Study. <i>Clinical Infectious Diseases</i> , 2019, 69, 1771-1779.	2.9	41
66	Modulation of Neutrophil-Mediated Activity Against the Pseudohyphal Form of <i>Candida albicans</i> by Granulocyte Colony-Stimulating Factor (G-CSF) Administered In Vivo. <i>Journal of Infectious Diseases</i> , 1999, 179, 1301-1304.	1.9	40
67	Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation. <i>Bone Marrow Transplantation</i> , 2002, 30, 945-951.	1.3	40
68	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Immune Dysregulation and Pathobiology Working Group Report. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 870-881.	2.0	38
69	Fewer infections and lower infection-related mortality following non-myeloablative versus myeloablative conditioning for allotransplantation of patients with lymphoma. <i>Bone Marrow Transplantation</i> , 2009, 43, 237-244.	1.3	37
70	Decreased Infections in Recipients of Unrelated Donor Hematopoietic Cell Transplantation from Donors with an Activating KIR Genotype. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 1155-1161.	2.0	37
71	Determinants of Human Immunodeficiency Virus DNA and RNA Shedding in the Anal-Rectal Canal of Homosexual Men. <i>Journal of Infectious Diseases</i> , 1998, 177, 571-578.	1.9	34
72	The impact of cytomegalovirus infection 1 year after primary renal transplantation. <i>Clinical Transplantation</i> , 2010, 24, 572-577.	0.8	33

#	ARTICLE	IF	CITATIONS
73	Infectious complications following unrelated cord blood transplantation. <i>Vox Sanguinis</i> , 2007, 92, 070302022831001-???.	0.7	32
74	Infections during mobilizing chemotherapy and following autologous stem cell transplantation. <i>Bone Marrow Transplantation</i> , 2001, 28, 1129-1134.	1.3	31
75	Time Trends in Fungal Infections as a Cause of Death in Hematopoietic Stem Cell Transplant Recipients. <i>American Journal of Clinical Pathology</i> , 2009, 132, 746-755.	0.4	31
76	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 2474-2481.	2.0	30
77	Role of new antifungal agents in prophylaxis of mycoses in high risk patients. <i>Current Opinion in Infectious Diseases</i> , 2005, 18, 479-483.	1.3	29
78	Risk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis. <i>Bone Marrow Transplantation</i> , 2016, 51, 277-282.	1.3	29
79	Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 171-183.	1.0	28
80	Preventing Measles in Immunosuppressed Cancer and Hematopoietic Cell Transplantation Patients: A Position Statement by the American Society for Transplantation and Cellular Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e321-e330.	2.0	26
81	No increased mortality from donor or recipient hepatitis B and/or hepatitis C positive serostatus after related donor allogeneic hematopoietic cell transplantation. <i>Transplant Infectious Disease</i> , 2012, 14, 468-478.	0.7	23
82	Cat-scratch disease relapse in a kidney transplant recipient. <i>Pediatric Transplantation</i> , 2007, 11, 105-109.	0.5	22
83	Itraconazole Therapy for Primary Cutaneous Aspergillosis in Patients with AIDS. <i>Clinical Infectious Diseases</i> , 1998, 27, 643-644.	2.9	17
84	Epidemiology and Management of Infectious Complications in Contemporary Management of Chronic Leukemias. <i>Infectious Disorders - Drug Targets</i> , 2011, 11, 3-10.	0.4	17
85	Infectious complications of acute and chronic GVHD. <i>Best Practice and Research in Clinical Haematology</i> , 2008, 21, 343-356.	0.7	16
86	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MBio</i> , 2016, 7, .	1.8	16
87	Toward revision of antimicrobial therapies in hematopoietic stem cell transplantation: target the pathogens, but protect the indigenous microbiota. <i>Translational Research</i> , 2017, 179, 116-125.	2.2	16
88	Outcome of CNS and pulmonary enteroviral infections after hematopoietic cell transplantation. <i>Pediatric Blood and Cancer</i> , 2005, 45, 74-75.	0.8	15
89	Pretransplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci (<i>E. gallinarum</i>) Tj ETQq1 1 0.784314 rgBT /Overlook <i>Blood and Marrow Transplantation</i> , 2018, 24, 1260-1263.	2.0	15
90	Specific Detection of Human BK Polyomavirus in Urine Samples of Immunocompromised Patients. <i>Vaccine Journal</i> , 2003, 10, 66-69.	3.2	11

#	ARTICLE	IF	CITATIONS
91	Bloodstream Infections in Hematologic Malignancy Patients With Fever and Neutropenia: Are Empirical Antibiotic Therapies in the United States Still Effective?. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	11
92	Is it time for a new look at granulocyte transfusions?. <i>Transfusion</i> , 2002, 42, 1393-1395.	0.8	10
93	A Review of Infections After Hematopoietic Cell Transplantation Requiring PICU Care: Transplant Timeline Is Key. <i>Frontiers in Pediatrics</i> , 2021, 9, 634449.	0.9	10
94	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Infection and Immunity</i> , 2016, 84, 2407-2408.	1.0	9
95	Symmetric Peripheral Gangrene. <i>New England Journal of Medicine</i> , 2001, 344, 1593-1593.	13.9	8
96	Early <i>Clostridioides difficile</i> infection characterizations, risks, and outcomes in allogeneic hematopoietic stem cell and solid organ transplant recipients. <i>Transplant Infectious Disease</i> , 2022, 24, e13720.	0.7	8
97	Recurrence of <i>Clostridium difficile</i> infection after total colectomy in an allogeneic stem cell transplant patient. <i>Bone Marrow Transplantation</i> , 2012, 47, 610-611.	1.3	7
98	Dasatinib-induced immunosuppression and recurrent respiratory tract infections. <i>Leukemia and Lymphoma</i> , 2015, 56, 2484-2485.	0.6	7
99	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Journal of Clinical Microbiology</i> , 2016, 54, 2216-2217.	1.8	7
100	Prophylactic Foscarnet for Human Herpesvirus 6: Effect on Hematopoietic Engraftment after Reduced-Intensity Conditioning Umbilical Cord Blood Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 84.e1-84.e5.	0.6	7
101	Systemic antifungal therapy with isavuconazonium sulfate or other agents in adults with invasive mucormycosis or invasive aspergillosis (non- <i>Aspergillus fumigatus</i>): A multicentre, non-interventional registry study. <i>Mycoses</i> , 2022, 65, 186-198.	1.8	7
102	Reservoir of <i>Candida albicans</i> infection in a vascular bypass graft demonstrates a stable karyotype over six months. <i>Medical Mycology</i> , 2004, 42, 255-260.	0.3	6
103	Preliminary Results from the AdVise Study Evaluating Brincidofovir (CMX001, BCV) for the Treatment of Disseminated and High-Risk Adenovirus (AdV) Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S108-S109.	2.0	6
104	Management of Infectious Diseases in Stem Cell Transplantation and Hematologic Malignancy. <i>Infectious Disease Clinics of North America</i> , 2019, 33, xiii-xv.	1.9	6
105	Secondary graft failure associated with parainfluenza virus infection following hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2005, 35, 425-425.	1.3	5
106	Human Metapneumovirus: Important but Not Currently Diagnosable. <i>Annals of Internal Medicine</i> , 2006, 144, 374.	2.0	5
107	Lethal small bowel necrosis due to aspergillosis during acute promyelocytic leukemia induction. <i>American Journal of Hematology</i> , 2013, 88, 329-332.	2.0	5
108	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MSphere</i> , 2016, 1, .	1.3	5

#	ARTICLE	IF	CITATIONS
109	More Infections with Transplantation of Bone Marrow, Versus Peripheral-Blood Stem Cells, from Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, S49-S50.	2.0	4
110	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Clinical Microbiology Reviews</i> , 2016, 29, i-ii.	5.7	4
111	Early <i>E. casseliflavus</i> gut colonization and outcomes of allogeneic hematopoietic cell transplantation. <i>PLoS ONE</i> , 2019, 14, e0220850.	1.1	4
112	Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection. <i>Transplant Infectious Disease</i> , 2019, 21, e13070.	0.7	4
113	Reply to Cornely et al.. <i>Clinical Infectious Diseases</i> , 2005, 40, 1699-1701.	2.9	3
114	Transformed large B-cell lymphoma in rituximab-allergic patient with chronic lymphocytic leukemia after allogeneic stem cell transplant: successful treatment with ofatumumab. <i>Leukemia and Lymphoma</i> , 2013, 54, 174-176.	0.6	3
115	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>MSystems</i> , 2016, 1, .	1.7	3
116	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5109-5110.	1.4	3
117	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>MBio</i> , 2020, 11, .	1.8	3
118	<i>Clostridioides difficile</i> infection in solid organ and hematopoietic stem cell transplant recipients: A prospective multinational study. <i>Transplant Infectious Disease</i> , 2022, 24, e13770.	0.7	3
119	Steroid-Sensitive, but Not Steroid-Dependent or Steroid-Resistant Acute Graft-versus-Host Disease, Results in Similar Infection Risk as No Graft-versus-Host Disease following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 509.e1-509.e11.	0.6	3
120	The ASM Journals Committee Values the Contributions of Black Microbiologists. <i>Journal of Microbiology and Biology Education</i> , 2020, 21, .	0.5	2
121	Beginning to understand clinical events and immune responses of hematopoietic cell transplant recipients receiving SARS-CoV-2 vaccination. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 700-701.	0.6	2
122	Infections in Recipients of Hematopoietic Cell Transplantation. , 2010, , 3821-3837.		2
123	Infections in Recipients of Hematopoietic Stem Cell Transplants. , 2015, , 3425-3439.e5.		2
124	Efficacy of posaconazole (POS) vs standard therapy and safety of POS in hematopoietic stem cell transplant (HSCT) recipients vs other patients with aspergillosis. <i>Biology of Blood and Marrow Transplantation</i> , 2006, 12, 137.	2.0	1
125	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Applied and Environmental Microbiology</i> , 2016, 82, 5479-5480.	1.4	1
126	ASM Journals Eliminate Impact Factor Information from Journal Websites. <i>Microbiology and Molecular Biology Reviews</i> , 2016, 80, i-ii.	2.9	1

#	ARTICLE	IF	CITATIONS
127	Typical and Atypical Mycobacterium Infections After Hematopoietic Stem Cell or Solid Organ Transplantation. , 2016, , 381-395.		1
128	The ASM Journals Committee Values the Contributions of Black Microbiologists. Journal of Clinical Microbiology, 2020, 58, .	1.8	1
129	The ASM Journals Committee Values the Contributions of Black Microbiologists. Applied and Environmental Microbiology, 2020, 86, .	1.4	1
130	The ASM Journals Committee Values the Contributions of Black Microbiologists. MSphere, 2020, 5, .	1.3	1
131	Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia.. Blood, 2012, 120, 3081-3081.	0.6	1
132	The ASM Journals Committee Values the Contributions of Black Microbiologists. Clinical Microbiology Reviews, 2020, 33, .	5.7	1
133	Fewer early bacterial and viral infections following non-myeloablative vs. myeloablative conditioning for allotransplantation. Biology of Blood and Marrow Transplantation, 2006, 12, 32.	2.0	0
134	Treatment of zygomycosis: Posaconazole as a treatment option in 91 cases. Biology of Blood and Marrow Transplantation, 2006, 12, 139.	2.0	0
135	Identification of Pathogenic Fungi. Clinical Infectious Diseases, 2014, 59, 1044-1045.	2.9	0
136	Similar Invasive Fungal Infection Rates and Survival after Allogeneic Hematopoietic Cell Transplantation with Umbilical Cord Blood and Bone Marrow or Peripheral Blood Graft Sources. Biology of Blood and Marrow Transplantation, 2016, 22, S174-S175.	2.0	0
137	Favorable Outcomes in Patients with Pre-Transplant Gut Colonization with Intrinsically Vancomycin-Resistant Enterococci. Biology of Blood and Marrow Transplantation, 2018, 24, S84-S85.	2.0	0
138	Evaluation and Management of Bacterial and Fungal Infections in Patients with a Hematological Malignancy: A 2018 Update. , 2018, , 1063-1078.		0
139	The ASM Journals Committee Values the Contributions of Black Microbiologists. Infection and Immunity, 2020, 88, .	1.0	0
140	The ASM Journals Committee Values the Contributions of Black Microbiologists. Microbiology Spectrum, 2020, 8, .	1.2	0
141	The ASM Journals Committee Values the Contributions of Black Microbiologists. Antimicrobial Agents and Chemotherapy, 2020, 64, .	1.4	0
142	The ASM Journals Committee Values the Contributions of Black Microbiologists. Journal of Virology, 2020, 94, .	1.5	0
143	Long-Term Infectious and Noninfectious Outcomes of Monthly Alemtuzumab as a Calcineurin Inhibitor- and Steroid-Free Regimen for Pancreas Transplant Recipients. Canadian Journal of Infectious Diseases and Medical Microbiology, 2020, 2020, 1-12.	0.7	0
144	The ASM Journals Committee Values the Contributions of Black Microbiologists. Journal of Bacteriology, 2020, 202, .	1.0	0

#	ARTICLE	IF	CITATIONS
145	The ASM Journals Committee Values the Contributions of Black Microbiologists. Microbiology and Molecular Biology Reviews, 2020, 84, .	2.9	0
146	The ASM Journals Committee Values the Contributions of Black Microbiologists. MSystems, 2020, 5, .	1.7	0
147	The ASM Journals Committee Values the Contributions of Black Microbiologists. Microbiology Resource Announcements, 2020, 9, .	0.3	0
148	Both "Small Ball" and "Big Inning" Teams Are Progressing the Value of Antifungal Prophylaxis Among Patients With Hematologic Malignancy. Clinical Infectious Diseases, 2021, 72, 1764-1766.	2.9	0
149	Prophylaxis for Aspergillosis. , 0, , 479-489.		0
150	The ASM Journals Committee Values the Contributions of Black Microbiologists. Molecular and Cellular Biology, 2020, 40, .	1.1	0
151	2021 Acknowledgment of CMR Reviewers. Clinical Microbiology Reviews, 2022, 35, e0024021.	5.7	0